Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + Lenalidomide + Dexamethasone in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
2020-005826-27Phase 2Active
- Sponsor
- Hellenic Society of Hematology
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Part 1 primary endpoint. Started Jan 2021; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-005826-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005826-27.